{
  "abstract": "ObjectiveAmphetamine (AMP) and its derivates are commonly prescribed for the management of attention-deficit/hyperactivity disorder (ADHD). This study aimed to 1) quantify AMPs transfer into human milk in lactating women receiving therapeutic doses and 2) contextualize infant exposure.\n\nMethodsMilk samples and dyad health histories of thirteen lactating women treated with varying doses of either mixed AMP, dextroamphetamine, or lisdexamfetamine were released for this study from the InfantRisk Human Milk Biorepository. Milk drug concentrations were quantified by validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) and used to calculate standard relative infant dose (RIDmat) and RID standardized to the defined daily dose (RIDDDD) of 15 mg AMP base.\n\nResultsAverage milk concentrations (Cavg) of AMP base ranged from 23.3 to 297.0 ng/mL and increased linearly (R{superscript 2} = 0.92) with maternal daily dose. The RIDmat ranged 3.6-10.8% and RIDDDD ranged 1.4-21.8%. The fitted regression line crossed the 10% RIDDDD threshold at 1.17x DDD, with the upper 95% prediction limit crossing at 0.84x DDD. No adverse event reported by the mother-infant dyads were attributed to AMP exposure, notably including absence of reduced milk supply.\n\nConclusionsThe levels of AMP observed in human milk followed a dose predictable manner. The average patient was predicted to remain below the 10% RID DDD safety threshold at total daily doses at or below approximately 28 mg of mixed AMP salts or 59 mg of lisdexamfetamine. Ninety-five percent of patients were predicted to remain below the threshold at or below approximately 20 mg and 40 mg, respectively.",
  "abstract_shown": true,
  "affiliations": [
    "InfantRisk Center of Excellence, Texas Tech University Health Sciences Center, Amarillo, Texas"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "name": "E. Yamada"
    },
    {
      "name": "A. Stark"
    },
    {
      "name": "J. Burdine"
    },
    {
      "name": "L. Donikini"
    },
    {
      "name": "P. Datta"
    },
    {
      "affs": [
        0
      ],
      "name": "K. Krutsch"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a3vvt95kw1cz2.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.10.14.26365136",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365136v1.full",
  "id": "a3vvt95kw1cz2",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365136v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "psychiatry and clinical psychology"
    ],
    [
      "openalex",
      "2739|Pregnancy and Medication Impact"
    ]
  ],
  "openalex": "W7222998174",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365136v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-14",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/a3vvt95kw1cz2.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:18Z",
      "native_id": "10.64898/2026.10.14.26365136",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.10.14.26365136v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:psychiatry and clinical psychology",
      "subfield": "psychiatry"
    }
  ],
  "title": "Focus or Feeding: A Quantitative Analysis of Prescribed Amphetamines in Human Milk",
  "title_text": "Focus or Feeding: A Quantitative Analysis of Prescribed Amphetamines in Human Milk",
  "type": "preprint",
  "updated_at": "2026-10-30T12:21:18Z",
  "url": "https://research.draconitic.com/paper/a3vvt95kw1cz2",
  "venue": "medRxiv",
  "versions": []
}